Open an account

Surmodics

SRDX · NASDAQ

Price unavailable right now.

No price history for this range.

About SRDX

Surmodics, Inc. engages in the provision of surface modification technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays. The company is headquartered in Eden Prairie, Minnesota and currently employs 389 full-time employees. The company also develops and commercializes highly differentiated vascular intervention medical devices that are designed to address unmet clinical needs and engineered to the demanding requirements. Its segments include Medical Device and IVD. Medical Device segment manufactures and licenses performance coatings, including surface modification coating technologies to improve access, deliverability and predictable deployment of medical devices and drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device, with end markets that include neurovascular, peripheral and coronary. IVD segment manufactures chemical and biological components used in in vitro diagnostic immunoassay and molecular tests within the diagnostic and biomedical research markets.

Employees
389
Headquarters
Eden Prairie, Minnesota
Listed
Mar 4, 1998
Sector
Health Care
Industry
Health Care Equipment & Supplies
Website
surmodics.com

SRDX key statistics

This section is temporarily unavailable. Refresh to try again.

Analyst ratings

Latest rating from each analyst over the past 12 months

0%of 1 analyst rating say Buy
  • Buy0.0%
  • Hold0.0%
  • Sell100.0%
Price target · 3 analystsAvg $43.86
Low
$43.43
High
$45.15

SRDX earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 7 of the last 8 quarters, by 106.0% on average.

  1. Q4 FY23: reported $0.53 per share against an estimate of $0.1887
  2. Q1 FY24: reported $0.00 per share against an estimate of -$0.3087
  3. Q2 FY24: reported $0.07 per share against an estimate of -$0.3264
  4. Q3 FY24: reported -$0.27 per share against an estimate of -$0.3366
  5. Q4 FY24: reported -$0.13 per share against an estimate of -$0.2999
  6. Q1 FY25: reported -$0.13 per share against an estimate of -$0.1156
  7. Q2 FY25: reported $0.06 per share against an estimate of -$0.1907
  8. Q3 FY25: reported $0.06 per share against an estimate of -$0.1907

SRDX news

  • Vandana Singh

    Medtech Integer Could Be More Valuable As A Private Company - Activist Investor Urges Strategic Review

  • Press releaseBusiness Wire

    Surmodics Announces FTC Does Not Intend to Appeal Denial of Injunction, Order Preventing Closing Set to Expire Today

  • Avi Kapoor

    Dow Gains More Than 300 Points; Energy Vault Holdings Shares Jump

  • 12 Health Care Stocks Moving In Tuesday's Intraday Session

  • Avi Kapoor

    US Stocks Mixed; Sea Shares Gain After Q3 Results

  • Press releaseBusiness Wire

    Surmodics Announces U.S. District Court Denies Request for Preliminary Injunction to Block Proposed Acquisition by GTCR

  • 12 Health Care Stocks Moving In Monday's Pre-Market Session

  • Press releaseBusiness Wire

    Surmodics Announces Outcomes from 160 Patients in PROWL Registry Evaluating Pounce™ Thrombectomy Platform in Treatment of Real-World Limb Ischemia Presentations

Similar companies

Companies in the same industry as Surmodics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.